Workflow
Antiviral treatments
icon
Search documents
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Globenewswire· 2025-09-15 20:30
Group 1 - Cocrystal Pharma, Inc. closed a registered direct offering, raising approximately $4.7 million from the sale of 2,764,710 shares at a price of $1.70 per share [1][3] - The company also issued unregistered warrants for the purchase of up to 5,529,420 shares at an exercise price of $1.50 per share, potentially adding approximately $8.3 million in gross proceeds if fully exercised [1][3] - The net proceeds from the offering will be used for working capital and general corporate purposes [3] Group 2 - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2] - The common stock was offered under a "shelf" registration statement effective since May 26, 2023, with a final prospectus supplement filed with the SEC [4] - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act [5] Group 3 - Cocrystal Pharma is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [7]
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Globenewswire· 2025-09-12 13:43
Group 1 - Cocrystal Pharma, Inc. has entered into definitive agreements for the purchase and sale of 2,764,710 shares of its common stock at a price of $1.70 per share, with gross proceeds expected to be approximately $4.7 million [1][3] - In a concurrent private placement, the company will issue unregistered warrants to purchase up to 5,529,420 shares of common stock at an exercise price of $1.50 per share, potentially adding approximately $8.3 million in gross proceeds if fully exercised [1][3] - The offering is expected to close on or about September 15, 2025, subject to customary closing conditions [1] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The net proceeds from the offering are intended for working capital and general corporate purposes [3] Group 3 - The common stock is being offered under a "shelf" registration statement that was declared effective by the SEC on May 26, 2023 [4] - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act [5] Group 4 - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [7]
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Globenewswire· 2025-09-03 12:00
Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [3] - The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs [3] Upcoming Event - James Martin, CFO and co-CEO of Cocrystal, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 12:00 p.m. Eastern time [1] - Mr. Martin will be available for in-person and virtual one-on-one meetings throughout the conference [2] - Institutional investors and industry professionals can register to attend the conference either virtually or in-person at the Lotte New York Palace Hotel [2]